Article Sidebar

Download
Requires Subscription PDF
Statistic
Read Counter : 282 Download : 2

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Main Article Content

Abstract

BACKGROUND


Diabetes mellitus (DM) is a common disease that causes high blood sugar levels and a wide range of symptoms, including polydipsia, polyuria, and changes in weight. The A1C level is very important when it comes to the main treatment for diabetes. It's called the A1C level because it shows the average blood glucose level over the last two to three months. People with diabetes are treated with lifestyle changes and a combination of pharmacological agents to keep their blood sugar levels in check for a long time. The objective of this study was to evaluate the information about Metformin and other Sulfonylureas for Glycemic Control in Type 2 Diabetic Patients at a Tertiary Care Hospital in Jammu & Kashmir.


METHODS


A 4 month-long observational study was set up with a prospective design and a convenient sampling method. From a diabetes clinic in Jammu and Kashmir, 200 people were chosen to be part of the study. People between the ages of 20 and 60 who had diabetes and were taking Metformin and Sulfonylureas were included in this study. People who had Retinopathy, Nephropathy, and Cognitive impairment were not included.


RESULTS


In our study, 34 percent of the people who went to the Diabetic Management Center of the hospital were men, and 66 percent were women. Out of 200 patients, 85 percent of them had time to exercise, 56 percent had diabetes because it ran in their families, and 44 percent had diabetes because of metabolic causes. Metformin was given to about 80% of the patients, and sulfonylureas were used by only 20% of the people. In a very bad situation, out of 50 people who took the survey, only 5% used insulin. HbA1C tests were ordered for 90% of the patients in the group of 200.


CONCLUSIONS


All over the world, people are suffering from type II diabetes. Several other metabolic disorders are linked to type II diabetes. Excessive hepatic glucose generation, peripheral insulin resistance, and impaired beta-cell secretory activity are the primary pathological abnormalities in diabetes. When it comes to glycemic control, Metformin does not raise insulin levels, but it does reduce the amount of glucose absorbed from the intestines. Sulfonylureas reduce hypoglycemia in metabolic disorders.

Keywords

Metformin, Sulfonylureas, Type 2 Diabetes Mellitus.

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite
Mohd Altaf Dar, Mudasir Maqbool, & Irfat Ara. (2023). Metformin and Other Sulfonylureas for Glycemic Control in Type 2 Diabetic Patients at a Tertiary Care Hospital in Jammu & Kashmir. Journal of Evolution of Medical and Dental Sciences, 12(6), 197–201. https://doi.org/10.14260/jemds.v12i6.428
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. International Journal of Molecular Sciences 2020;21(17):6275.
  2. Eizirik DL, Pasquali L, Cnop M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nature Reviews Endocrinology 2020;16(7):349-62.
  3. Targher G, Corey KE, Byrne CD, et al. The complex link between NAFLD and type 2 diabetes mellitus-mechanisms and treatments. Nature reviews Gastroenterology & Hepatology 2021;18(9):599-612.
  4. Artasensi A, Pedretti A, Vistoli G, et al. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules 2020;25(8):1987.
  5. Zehravi M, Maqbool M, Ara I. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. Open Health 2022;3(1):60-5.
  6. Dar MA, Maqbool M, Gani I, et al. Menstruation hygiene and related issues in adolescent girls: a brief commentary. International Journal of Current Research in Physiology and Pharmacology 2023:1-5.
  7. Maqbool M, Ara I, Gani I. The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age. International Journal of Current Research in Physiology and Pharmacology 2022;6(3):19-31.
  8. Ara I, Maqbool M, Zehravi M. Psychic consequences of infertility on couples: a short commentary. Open Health 2022;3(1):114-9.
  9. Zehravi M, Maqbool M, Ara I. Teenage menstrual dysfunction: an overview. International Journal of Adolescent Medicine and Health 2022;35(1):15-9.
  10. Ara I, Maqbool M, Gani I. Reproductive Health of Women: Implications and attributes. International Journal of Current Research in Physiology and Pharmacology 2022:8-18.
  11. Ara I, Maqbool M, Gani I. Role of Insulin Resistance in Gestational Diabetes Mellitus: A Literature Review. Chettinad Health City Medical Journal (E-2278-2044 & P-2277-8845). 2022;11(2):69-74.
  12. Ara I, Maqbool M, Gani I. Neuroprotective activity of herbal medicinal products: a review. International Journal of Current Research in Physiology and Pharmacology 2022;6(4):1-10.
  13. Ara I, Zehravi M, Maqbool M, et al. A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries. J Pharma Res Rep 2022;3(2):1-8.
  14. D.J. Magliano, J.W. Sacre, J.L. Harding, E.W. Gregg, P.Z. Zimmet, J.E. Shaw, Young-onset type 2 diabetes mellitus—Implications for morbidity and mortality, Nature Reviews Endocrinology 16(6) (2020) 321-331.
  15. C. Arnott, Q. Li, A. Kang, B.L. Neuen, S. Bompoint, C.S. Lam, A. Rodgers, K.W. Mahaffey, C.P. Cannon, V. Perkovic, Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis, Journal of the American Heart Association 9(3) (2020) e014908.
  16. Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews Endocrinology 2021;17(8):484-95.
  17. Maqbool M, Nasir N, Mustafa S. Polycystic in ovarian syndrome and its various treatment strategies. Indo American Journal of Pharmaceutical Sciences 2018;5(9):8470-8.
  18. Maqbool M, Zehravi M, Maqbool R, et al. Study of adverse drug reactions in pulmonary medicine department of a tertiary care hospital, Srinagar, Jammu & Kashmir, India. CELLMED 2021;11(2):8.1-8.5.
  19. Maqbool R, Maqbool M, Zehravi M, et al. Menstrual distress in females of reproductive age: a literature review. International Journal of Adolescent Medicine and Health 2021;34(2):11-7.
  20. Zehravi M, Maqbool M, Ara I. An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India. The Indian Journal of Nutrition and Dietetics 2021;58(3):408-18.
  21. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. International Journal of Adolescent Medicine and Health 2021;34(2):1-9.
  22. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. International Journal of Adolescent Medicine and Health 2021;33(6):367-73.
  23. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. International Journal of Adolescent Medicine and Health 2021;33(6):333-7.
  24. Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology 2020;16(10):545-55.
  25. Pérez-Belmonte LM, Torres-Peña JD, López-Carmona MD, et al. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Medicine 2020;18(1):1-10.
  26. Nanayakkara N, Curtis AJ, Heritier S, et al. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia 2021;64(2):275-87..
  27. Krentz NA, Gloyn AL. Insights into pancreatic islet cell dysfunction from type 2 diabetes mellitus genetics. Nature Reviews Endocrinology 2020;16(4):202-12.
  28. Cosentino F, Cannon CP, Cherney DZ, et al. Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV Trial. Circulation 2020;142(23):2205-15.
  29. Vesa CM, Popa L, Popa AR, et al. Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors. Diagnostics 2020;10(5):314.
  30. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets and Therapy 2022;14:15-24.
  31. Maqbool M, Dugassa D, Fekadu G. Adverse drug reactions of antiepileptic drugs in the neurology department of a tertiary care hospital, Srinagar, Jammu & Kashmir, India. Archives of Neuroscience 2021;8(2):e112364.
  32. Maqbool M, Fekadu G, Jiang X, et al. An up to date on clinical prospects and management of osteoarthritis. Annals of Medicine and Surgery 2021;72:103077.
  33. Chawla R, Madhu SV, Makkar BM, et al. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism 2020;24(1):1.
  34. Li Z, Cheng Y, Wang D, et al. Incidence rate of type 2 diabetes mellitus after gestational diabetes mellitus: a systematic review and meta-analysis of 170,139 women. Journal of Diabetes Research 2020;2020:3076463.
  35. Faselis C, Katsimardou A, Imprialos K, et al. Microvascular complications of type 2 diabetes mellitus. Current Vascular Pharmacology 2020;18(2):117-24.
  36. Rachdaoui N. Insulin: the friend and the foe in the development of type 2 diabetes mellitus. International Journal of Molecular Sciences 2020;21(5):1770.
  37. Al Mansour MA. The prevalence and risk factors of type 2 diabetes mellitus (DMT2) in a semi-urban Saudi population. International Journal of Environmental Research and Public Health 2020;17(1):7.
  38. Karatas S, Yesim T, Beysel S. Impact of lockdown COVID-19 on metabolic control in type 2 diabetes mellitus and healthy people. Primary care diabetes 2021;15(3):424-7.
  39. E Mikhael EM, Hassali MA, Hussain SA. Effectiveness of diabetes self-management educational programs for type 2 diabetes mellitus patients in Middle East countries: a systematic review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020;13:117.
  40. Izzo A, Massimino E, Riccardi G, et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients 2021;13(1):183.
  41. Perreault L, Skyler JS, Rosenstock J. Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nature Reviews Endocrinology 2021;17(6):364-77.